Dipeptidyl Peptidase-4 Is a Target Protein of Epigallocatechin-3-Gallate

被引:11
|
作者
Hou, Huimin [1 ]
Wang, Ying [2 ]
Li, Chunshi [2 ]
Wang, Jian [2 ]
Cao, Yanli [1 ]
机构
[1] China Med Univ, Affiliated Hosp 1, Liaoning Prov Key Lab Endocrine Dis, Dept Endocrinol & Metab,Inst Endocrinol, Shenyang, Liaoning, Peoples R China
[2] Shenyang Pharmaceut Univ, Minist Educ, Key Lab Struct Based Drug Design & Discovery, Shenyang, Liaoning, Peoples R China
基金
中国国家自然科学基金;
关键词
GREEN TEA POLYPHENOL; MOLECULAR DOCKING; (-)-EPIGALLOCATECHIN GALLATE; COMPLEX; HEALTH; INHIBITION; PREVALENCE; REVEALS; EGCG;
D O I
10.1155/2020/5370759
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Epigallocatechin-3-gallate (EGCG), a major active ingredient in green tea, has various health benefits. It affects glucose metabolism, but the mechanism is not well understood. This study aimed to identify targets of EGCG related to glucose metabolism. The core fragment of EGCG is a flavonoid. The flavonoid scaffold was used as a substructure to find proteins cocrystallized with flavonoids in the Protein Data Bank. The proteins identified were screened in PubMed for known relationships with diabetes. Dipeptidyl peptidase-4 (DPP4; PDB 5J3J) was identified following this approach. By molecular docking, the interactions of EGCG and DPP4 were assessed. To test the stability of the interactions between EGCG and DPP4, molecular dynamics simulation for 100 ns was performed using Desmond software. In vitro, the concentration of EGCG required to inhibit DPP4 activity by 50% (the IC50 value) was 28.42 mu M. These data provide a theoretical basis for intervention in glucose metabolism with EGCG.
引用
收藏
页数:9
相关论文
共 50 条
  • [1] Dipeptidyl Peptidase-4 Inhibitors: 3 Years of Experience
    Derosa, Giuseppe
    Maffioli, Pamela
    [J]. DIABETES TECHNOLOGY & THERAPEUTICS, 2012, 14 (04) : 350 - 364
  • [2] Dipeptidyl peptidase-4 inhibitors and osteoporosis
    Lee, Wen-Ling
    Lee, Fa-Kung
    Wang, Peng-Hui
    [J]. JOURNAL OF THE CHINESE MEDICAL ASSOCIATION, 2022, 85 (09) : 889 - 890
  • [3] Dipeptidyl peptidase-4 inhibitor approaches
    Bloomgarden, Zachary
    [J]. JOURNAL OF DIABETES, 2017, 9 (01) : 5 - 7
  • [4] The role of dipeptidyl peptidase-4 inhibitors
    Lasserson, Daniel
    Mant, Jonathan
    [J]. BRITISH MEDICAL JOURNAL, 2012, 344
  • [5] ERα36 is an effective target of epigallocatechin-3-gallate in hepatocellular carcinoma
    Chen, Jing
    Chen, Lihong
    Lu, Ting
    Xie, Yuqiong
    Li, Chunchun
    Jia, Zhenyu
    Cao, Jiang
    [J]. INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2019, 12 (09): : 3222 - 3234
  • [6] The role of renal dipeptidyl peptidase-4 in kidney disease: renal effects of dipeptidyl peptidase-4 inhibitors with a focus on linagliptin
    Kanasaki, Keizo
    [J]. CLINICAL SCIENCE, 2018, 132 (04) : 489 - 507
  • [7] The role of Dipeptidyl Peptidase-4 in cutaneous disease
    Patel, Payal M.
    Jones, Virginia A.
    Kridin, Khalaf
    Amber, Kyle T.
    [J]. EXPERIMENTAL DERMATOLOGY, 2021, 30 (03) : 304 - 318
  • [8] Renal outcomes with dipeptidyl peptidase-4 inhibitors
    Scheen, A. J.
    Delanaye, P.
    [J]. DIABETES & METABOLISM, 2018, 44 (02) : 101 - 111
  • [9] Heart failure and dipeptidyl peptidase-4 inhibitors
    Krum, Henry
    Skiba, Marina
    Wu, Shiying
    Hopper, Ingrid
    [J]. EUROPEAN JOURNAL OF HEART FAILURE, 2014, 16 (06) : 603 - 607
  • [10] Cardiovascular effects of dipeptidyl peptidase-4 inhibitors
    Papagianni, M.
    Tziomalos, K.
    [J]. HIPPOKRATIA, 2015, 19 (03) : 195 - 199